In order to provide faster identification of bloodstream pathogens, bioMérieux (Euronext: BIM) has agreed with AdvanDx, Inc. to sign an exclusive distribution agreement for the United States for AdvanDx’s PNA FISH™ rapid diagnostic tests. These tests will be displayed at bioMérieux’s booth from the opening of the American Society of Microbiology (ASM) in Toronto on May 22.
bioMérieux and LabTech Systems sign exclusive worldwide license agreement for innovative robotic microbiological instrumentation
Wed, 18/04/2007
LabTech Systems Ltd (ASX: LBT), an Australian health care equipment and services company, and bioMérieux (Euronext: BIM), a world leader in the field of in vitro diagnostics, announced today that they have signed an exclusive worldwide license agreement for LabTech Systems’ automated pre-poured media (PPM) streaker known as MicroStreak®.
bioMérieux Launches VIDAS® B·R·A·H·M·S PCT, a Procalcitonin Measurement Test Allowing Early Detection of Severe Bacterial Infections
Fri, 30/03/2007
bioMérieux, a global leader in the field of in vitro diagnostics, today announces the launch of VIDAS® B·R·A·H·M·S PCT. This new, CE approved test, was developed following the licensing agreement signed with B·R·A·H·M·S, enabling bioMérieux to develop, produce and market a test for measuring procalcitonin (PCT) levels. The test is sensitive and specific, used in the early detection of severe bacterial infections (e.g. sepsis).
Scotland chooses VITEK® 2 for all NHS Microbiology Laboratories
Mon, 19/03/2007
National Procurement, a division of NHS National Services Scotland and the Scottish Microbiology Forum have awarded bioMérieux with a major contract to supply each of the 27 NHS (National Health Service) clinical microbiology laboratories in the country with a VITEK 2 system for standardising antibiotic susceptibility testing (AST) and bacterial identification.
bioMérieux Receives Major Order from BML, Japan’s Biggest Laboratory Chain
Tue, 06/03/2007
bioMérieux, a global leader in the field of in vitro diagnostics, announces today that it has received a major order from BML, Inc. (BioMedical Laboratories), the biggest Japanese private laboratory chain. bioMérieux will supply 28 VITEK® 2 XL to BML.
bioMérieux confirms its commitment to the fight against Hospital Acquired Infections
Thu, 15/02/2007
bioMérieux, a global leader in the field of in vitro diagnostics, confirms its commitment to the fight against Hospital Acquired Infections with the launch of three new products.
bioMérieux and ExonHit Therapeutics initiate their third diagnostic program
Thu, 04/01/2007
Screening of prostate cancer from blood. bioMérieux and ExonHit Therapeutics announce, today, the initiation of their third programme for the screening of cancer from blood. One of the goals is to assist physicians in deciding whether to proceed with surgery for prostate cancer.
